JIC
VRTX icon

Joel Isaacson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Joel Isaacson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
575
+69
+14% +$30.6K 0.01% 392
2026
Q1 		$226K Buy
506
+14
+3% +$6.53K 0.01% 413
2025
Q4 		$223K Buy
+492
New +$212K 0.01% 419
2025
Q3 		– Sell
-454
Closed -$202K – 455
2025
Q2 		$202K Hold
454
– – 0.01% 401
2025
Q1 		$220K Buy
+454
New +$212K 0.01% 362
2024
Q3 		– Sell
-469
Closed -$220K – 379
2024
Q2 		$220K Buy
+469
New +$204K 0.01% 317
2015
Q3 		– Sell
-1,150
Closed -$142K – 777
2015
Q2 		$142K Hold
1,150
– – 0.04% 210
2015
Q1 		$136K Hold
1,150
– – 0.03% 215
2014
Q4 		$137K Buy
+1,150
New +$130K 0.04% 197

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Joel Isaacson & Co's VRTX Position: Q2 2026 in Review

Joel Isaacson & Co increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $30.6K and bringing the position to 575 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #392.

Joel Isaacson & Co first reported a position in VRTX in Q4 2014 and has held it in 9 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Joel Isaacson & Co held 575 shares of Vertex Pharmaceuticals worth $286K as of Q2 2026.
  • Joel Isaacson & Co bought 69 Vertex Pharmaceuticals shares in Q2 2026, an estimated $30.6K.
  • Vertex Pharmaceuticals made up 0.01% of Joel Isaacson & Co's portfolio in Q2 2026, its #392 holding.
  • Joel Isaacson & Co first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 9 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.